B. Braun Secures Major Legal Victories in Ethylene Oxide Cases

BETHLEHEM, Pa. – January 13, 2026 – Medical technology giant B. Braun US Device Manufacturing LLC has scored a pair of significant legal victories that strengthen its defense against claims related to its use of ethylene oxide (EtO), a chemical essential for sterilizing medical equipment but also classified as a carcinogen.

In a decision that could influence similar environmental litigation nationwide, the Court of Common Pleas of Lehigh County has denied a request to certify a class action lawsuit against the company. The ruling deals a major blow to a suit that sought to establish a medical monitoring program for the community surrounding B. Braun's Allentown, Pennsylvania, sterilization facility.

This decision follows a December 2024 defense verdict in a separate Philadelphia case, where a jury found B. Braun not negligent and not liable on all counts. According to the company, these favorable outcomes prompted the resolution of a majority of other pending cases against it. B. Braun stated it “welcomes the Lehigh County court decision and the defense verdict and will continue to defend against any of these cases.”

A Critical Ruling on Class Action

The case, Mourad Abdelaziz v. B. Braun US Device Manufacturing LLC, was brought by a local resident who claimed the company's use of EtO increased his and other residents' potential health risks. The core of the lawsuit was a demand for a court-mandated medical monitoring fund to cover the costs of screening for diseases allegedly linked to EtO exposure.

After reviewing extensive testimony, the court issued a detailed 49-page decision, concluding that the lawsuit did not satisfy “nearly all of the requirements of a class action” under Pennsylvania law. A key factor in the court's reasoning was its finding that several of the plaintiff's expert witnesses were unreliable. Without credible expert testimony to establish common issues across a large group of people, the legal foundation for a class action crumbled.

The denial of class certification fundamentally alters the legal path forward. Instead of facing a single, high-stakes lawsuit representing an entire community, B. Braun now faces the prospect of defending against individual claims, which are often more complex and costly for plaintiffs to pursue. This type of ruling often discourages further litigation by making it economically and logistically unfeasible for individual plaintiffs.

Navigating a National Litigation Minefield

B. Braun’s recent successes stand in stark contrast to the costly outcomes faced by other companies in the medical sterilization industry. Ethylene oxide is used to sterilize roughly half of all medical devices in the United States, but its classification as a human carcinogen by the Environmental Protection Agency (EPA) has made it a flashpoint for legal and regulatory battles across the country.

Sterigenics, a major sterilization provider, has been a prominent target. In 2022, an Illinois jury awarded a staggering $363 million to a cancer survivor who alleged her illness was caused by emissions from the company's now-shuttered Willowbrook plant. While that award was later reduced, Sterigenics ultimately agreed to a $408 million settlement in 2023 to resolve hundreds of similar lawsuits in Illinois. Likewise, medical device manufacturer BD (Becton Dickinson) has faced lawsuits over EtO emissions from its facilities in Georgia.

Against this backdrop, B. Braun’s strategy of challenging expert testimony and the fundamental criteria for class actions has proven remarkably effective. The company's legal team successfully argued that individual factors—such as a person's lifestyle, genetics, and proximity to the plant—made it impossible to treat the community's claims as a single, unified case.

The Unresolved Dilemma: Medical Need vs. Public Health

At the heart of the controversy is the indispensable role EtO plays in modern healthcare. It is the only viable method for sterilizing a vast array of heat-sensitive and delicate medical devices, from catheters and syringes to complex surgical kits. A sudden halt to its use could trigger catastrophic shortages of life-saving equipment.

Yet, the public health concerns are significant. The EPA's re-evaluation of EtO's toxicity in 2016 spurred heightened community awareness and regulatory action. In March 2024, the agency finalized stringent new rules under the National Emission Standards for Hazardous Air Pollutants (NESHAP) that will require commercial sterilizers to slash EtO emissions by more than 90%.

B. Braun has maintained that its operations are safe and compliant. In 2020, the company invested in an enhanced emission control system at its Allentown facility, which it claims reduced EtO emissions by over 99%. These legal victories may vindicate the company’s position in the courtroom, but the broader public debate over industrial emissions and community health continues.

The Path Forward: A Quest for Alternatives

While B. Braun fortifies its legal defenses, the entire medical device industry is under immense pressure to find alternatives to ethylene oxide. The Food and Drug Administration (FDA), which regulates medical device safety, has actively encouraged innovation in sterilization technology to reduce reliance on EtO and enhance the resilience of the medical supply chain.

Several alternative methods are being explored and adopted, including radiation-based techniques like gamma, E-beam, and X-ray sterilization, as well as chemical methods using vaporized hydrogen peroxide (VHP) or nitrogen dioxide (NO2). However, the transition is neither simple nor swift.

Each alternative comes with its own set of challenges. A primary hurdle is material compatibility; devices designed and validated over decades for EtO sterilization can be damaged by other methods. Switching requires extensive, costly, and time-consuming re-validation and regulatory approval from the FDA. Furthermore, building new facilities with alternative technologies requires massive capital investment. B. Braun's legal wins provide it with crucial stability, but like its peers, it must navigate a future where the long-term viability of EtO is increasingly in question, pushing the industry toward a new era of sterilization technology.